ATE372985T1 - N-alkyl-4-methylenamino-3-hydroxy-2-pyridone verwendbar als antimikrobielle mittel - Google Patents

N-alkyl-4-methylenamino-3-hydroxy-2-pyridone verwendbar als antimikrobielle mittel

Info

Publication number
ATE372985T1
ATE372985T1 AT03768776T AT03768776T ATE372985T1 AT E372985 T1 ATE372985 T1 AT E372985T1 AT 03768776 T AT03768776 T AT 03768776T AT 03768776 T AT03768776 T AT 03768776T AT E372985 T1 ATE372985 T1 AT E372985T1
Authority
AT
Austria
Prior art keywords
methyleneamino
pyridone
usable
hydroxy
alkyl
Prior art date
Application number
AT03768776T
Other languages
English (en)
Inventor
Namal Warshakoon
Rodney Bush
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Application granted granted Critical
Publication of ATE372985T1 publication Critical patent/ATE372985T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
AT03768776T 2002-11-09 2003-11-07 N-alkyl-4-methylenamino-3-hydroxy-2-pyridone verwendbar als antimikrobielle mittel ATE372985T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42507002P 2002-11-09 2002-11-09

Publications (1)

Publication Number Publication Date
ATE372985T1 true ATE372985T1 (de) 2007-09-15

Family

ID=32312926

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03768776T ATE372985T1 (de) 2002-11-09 2003-11-07 N-alkyl-4-methylenamino-3-hydroxy-2-pyridone verwendbar als antimikrobielle mittel

Country Status (26)

Country Link
US (5) US6930117B2 (de)
EP (1) EP1558579B1 (de)
JP (1) JP4496083B2 (de)
KR (2) KR100896675B1 (de)
CN (1) CN1708481A (de)
AT (1) ATE372985T1 (de)
AU (1) AU2003291382B2 (de)
BR (1) BR0316107A (de)
CA (1) CA2502264C (de)
CO (1) CO5570678A2 (de)
CY (1) CY1106958T1 (de)
DE (1) DE60316338T2 (de)
DK (1) DK1558579T3 (de)
EG (1) EG25017A (de)
ES (1) ES2293036T3 (de)
HR (1) HRP20050516B1 (de)
IL (1) IL168119A (de)
MA (1) MA27643A1 (de)
MX (1) MXPA05004896A (de)
NO (1) NO330810B1 (de)
NZ (1) NZ539386A (de)
PL (1) PL377226A1 (de)
PT (1) PT1558579E (de)
RU (1) RU2311410C2 (de)
WO (1) WO2004043927A1 (de)
ZA (1) ZA200503683B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6930117B2 (en) * 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
US7728013B2 (en) 2005-05-10 2010-06-01 Intermune, Inc. Method of modulating stress-activated protein kinase system
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TWI445532B (zh) 2007-09-14 2014-07-21 Janssen Pharmaceuticals Inc 1’,3’-二取代-4-苯基-3,4,5,6-四氫-2h,1’h-〔1,4’〕聯吡啶基-2’-酮化物
JP5433579B2 (ja) 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 1,3−二置換−4−フェニル−1h−ピリジン−2−オン
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
EP2296653B1 (de) 2008-06-03 2016-01-27 Intermune, Inc. Verbindungen und verfahren zur behandlung von entzündungserkrankungen und fibrotischen erkrankungen
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
ES2466341T3 (es) 2008-10-16 2014-06-10 Janssen Pharmaceuticals, Inc. Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MX2011011964A (es) 2009-05-12 2012-02-23 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos.
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
PL2451279T3 (pl) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
RU2521251C2 (ru) * 2009-11-06 2014-06-27 Аэрпио Терапьютикс Инк. Способы усиления стабилизации индуцируемого гипоксией фактора-1 альфа
AU2011223976B2 (en) * 2010-03-04 2015-05-21 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
JP5937971B2 (ja) 2010-03-04 2016-06-22 メルク・シャープ・エンド・ドーム・コーポレイション カテコールo−メチルトランスフェラーゼの阻害剤および精神障害の治療におけるその使用
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP3607821B1 (de) 2013-03-15 2022-08-03 EyePoint Pharmaceuticals, Inc. Zusammensetzungen, formulierungen und verfahren zur behandlung von augenerkrankungen
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
DK3096790T3 (da) 2014-01-21 2019-10-07 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
UA127921C2 (uk) 2014-01-21 2024-02-14 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
JP6549140B2 (ja) 2014-02-19 2019-07-24 エアーピオ セラピューティクス インコーポレイテッド N−ベンジル−3−ヒドロキシ−4−置換ピリジン−2−(1h)−オン
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
WO2017216726A1 (en) 2016-06-13 2017-12-21 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as inhibitors of dnmt1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US385390A (en) 1888-07-03 Sylvantjs l
US3852900A (en) * 1973-07-18 1974-12-10 J Svec Disc type indicia recording and display device
US3853900A (en) 1973-09-14 1974-12-10 Searle & Co 4-benzyloxy-2 (1h)-pyridones
DE2442714A1 (de) * 1974-09-06 1976-03-18 Benckiser Wassertechnik Joh A Verfahren und vorrichtung zum pumpen von fluessigkeiten mittels einer membrandosierpumpe
US5358949A (en) 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
DE4316077A1 (de) 1993-05-13 1994-11-17 Bayer Ag Substituierte Mono- und Bihydridylmethylpyridone
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
US6046219A (en) 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5849587A (en) 1995-06-09 1998-12-15 Cornell Research Foundation, Inc. Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
ATE438624T1 (de) 2000-12-28 2009-08-15 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones

Also Published As

Publication number Publication date
RU2311410C2 (ru) 2007-11-27
US8133894B2 (en) 2012-03-13
HRP20050516A2 (en) 2005-12-31
ZA200503683B (en) 2006-08-30
NZ539386A (en) 2008-02-29
EP1558579B1 (de) 2007-09-12
NO20052787L (no) 2005-06-09
BR0316107A (pt) 2005-09-27
CA2502264C (en) 2009-12-15
CY1106958T1 (el) 2012-09-26
CN1708481A (zh) 2005-12-14
PL377226A1 (pl) 2006-01-23
HRP20050516B1 (hr) 2013-11-08
NO20052787D0 (no) 2005-06-09
US6930117B2 (en) 2005-08-16
CO5570678A2 (es) 2005-10-31
RU2005114489A (ru) 2005-11-20
DK1558579T3 (da) 2008-01-14
KR20070026891A (ko) 2007-03-08
US20070270407A1 (en) 2007-11-22
JP2006508133A (ja) 2006-03-09
AU2003291382A1 (en) 2004-06-03
PT1558579E (pt) 2007-11-27
DE60316338T2 (de) 2008-06-05
CA2502264A1 (en) 2004-05-27
MA27643A1 (fr) 2005-12-01
EP1558579A1 (de) 2005-08-03
US7247648B2 (en) 2007-07-24
ES2293036T3 (es) 2008-03-16
AU2003291382B2 (en) 2008-07-31
MXPA05004896A (es) 2005-07-22
KR20050055792A (ko) 2005-06-13
US20100305097A1 (en) 2010-12-02
EG25017A (en) 2011-05-25
IL168119A (en) 2011-11-30
US20040097560A1 (en) 2004-05-20
NO330810B1 (no) 2011-07-25
KR100896675B1 (ko) 2009-05-08
DE60316338D1 (de) 2007-10-25
JP4496083B2 (ja) 2010-07-07
US20120115876A1 (en) 2012-05-10
WO2004043927A1 (en) 2004-05-27
US7790748B2 (en) 2010-09-07
US20050234045A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
ATE372985T1 (de) N-alkyl-4-methylenamino-3-hydroxy-2-pyridone verwendbar als antimikrobielle mittel
NO20052788L (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
ATE376996T1 (de) Antibakterielle mittel
NO20051082L (no) Antimikrobielle kinoloner, deres sammensetninger og anvendelser
ECSP003699A (es) Inhibidores de fab i
ATE516022T1 (de) Antimikrobielle zusammensetzungen und anwendungsverfahren dafür
ATE420639T1 (de) Antimykotische mittel
ATE433981T1 (de) Heterocyclische verbindungen
NO20062629L (no) Oksazolderivater av tetrackliner
ATE433963T1 (de) Fab-i inhibitoren
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
BG108498A (en) New derivatives of oxazolidinones as antibacterial agents
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
ATE403655T1 (de) Imidazopyridinderivate als induzierbare no- synthaseinhibitoren
ATE517108T1 (de) 9-(1',5'-dimethyl-1'-vinyl-4'-hexenyl)-4-hydrox - 7h-furoä3,2-güä1übenzopyran-7-on als antibakterielles mittel
ATE348803T1 (de) Tryptase-inhibitoren
ATE364037T1 (de) Tryptasehemmer
PT1358182E (pt) Derivados de diazocinas e sua utilizacao como inibidores de triptase
MY140242A (en) BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS
FI20020507A0 (fi) Antimikrobiaine patogeenisia bakteereita vastaan
EA200501830A1 (ru) Новые производные линкомицина, обладающие антимикробной активностью

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1558579

Country of ref document: EP